Riskpilot← Back to searchSign inGet full accessSanofi Oy
OYActiveY-tunnus 1048723-8Revontulenkuja 1Wholesale of pharmaceutical and medical goods · NACE 4646Est. 199572 employees
Revenue 2024
EUR 96M
+18% vs 2023
EBITDA margin
6.8%
+96% vs 2023
Equity ratio
31.1%
Financial strength
Net profit 2024
EUR 5M
+89% vs 2023
| Revenue | EUR 96M | +18% |
| EBITDA | EUR 6,6M | +96% |
| Net profit | EUR 5M | +89% |
| Total assets | EUR 50M | +17% |
| Equity | EUR 15,5M | +0% |
| Employees | 72 | — |
Legal name
Sanofi Oy
Y-tunnus number
1048723-8
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7. kesäkuuta 1995
Share capital
EUR 1 683 696
Employees
72 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on harjoittaa lääke- ja diagnostiikka-alan teollisuutta ja kauppaa sekä muuta näihin liittyvää taikka näiden yhteyteen soveltuvaa liiketoimintaa.
Address
Revontulenkuja 1
Phone
+3580201200300
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 97 814 | 95 218 | 84 235 | 81 420 | 95 991 |
| Staff expenses | −11 246 | −9 738 | −10 084 | −367 | −10 170 |
| EBITDA | 11 059 | 7 066 | 4 267 | 3 359 | 6 570 |
| Depreciation & amort. | −360 | −1 706 | −63 | −56 | −68 |
| EBIT | 10 699 | 5 359 | 4 204 | 3 303 | 6 502 |
| Net financials | −8 | −31 | −19 | 65 | −229 |
| Profit before tax | 10 691 | 5 328 | 4 185 | 3 365 | 6 273 |
| Tax | 2 180 | 1 084 | 908 | 740 | 1 315 |
| Net profit | 8 511 | 4 245 | 3 277 | 2 625 | 4 959 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 54 074 | 54 650 | 47 231 | 42 827 | 50 000 |
| Equity | 29 116 | 28 860 | 27 893 | 15 519 | 15 530 |
| Long-term debt | 1 238 | 1 881 | — | 0 | 0 |
| Short-term debt | 23 720 | 23 909 | 19 337 | 1 377 | 34 469 |
| Total debt | 24 958 | 25 790 | 19 337 | 27 308 | 34 469 |
EBITDA margin
6.8%
This company
15.8%
Market median
-57% vs market
20202024
Equity ratio
31.1%
This company
38.2%
Market median
+19% vs market
20202024
Return on equity
31.9%
This company
18.4%
Market median
+73% vs market
20202024
Net profit margin
5.2%
This company
8.1%
Market median
-36% vs market
20202024
Asset turnover
1.92×
This company
1.12×
Market median
+71% vs market
20202024
Debt / equity
2.22×
This company
0.62×
Market median
-258% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
ME Deputy Member | Deputy Member | 2025 |
RH Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (4) | ||
JM Chief Executive Officer | Chief Executive Officer | 2018 – 2023 |
PS Deputy Member | Deputy Member | 2023 – 2025 |
AA Deputy Member | Deputy Member | 2018 – 2022 |
| Audit | 2014 – 2023 | |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2025 | |
| Former (2) | ||
| Board of Directors | 2018 – 2019 | |
| Board of Directors | 2019 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sanofi Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jenni Marianna Vuola | Chief Executive Officer | 0 companies |
| Maria Elisabet Aalto-Setälä | Deputy Member | 0 companies |
| Patrik Samuel Kvarnström | Deputy Member | 0 companies |
| Anders August Nyman | Deputy Member | 0 companies |
| Bengt Christer Valdemar Nyholm | Audit | 0 companies |
| Ritva Helena Lehtonen | Chief Executive Officer | 0 companies |
| Alexandre Frédéric Favre | Board of Directors | 0 companies |
| Hao Zheng | Board of Directors | 0 companies |
| Pieter Wester Oldenziel | Board of Directors | 0 companies |